Antibody Information

General Information of This Antibody

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

PF-06647263 [Terminated in phase 1]

ADC Info

Identified from the Human Clinical Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Objective Response Rate (ORR)	10.40% (all dose-escalation groups) 9.10% (in the 0.015 mg/kg QW group )
Patients Enrolled	Advanced solid tumors resistant to standard therapy or for which no standard therapy.
Administration Dosage	Every 3 weeks (Q3W) or every week (QW), following a modified toxicity probability interval (mTPI) method (initial dosing: 0.015 mg/kg Q3W).
*Related Clinical Trial*
NCT Number	NCT02078752	Clinical Status	Phase 1
Clinical Description	A first-in-human phase 1, dose escalation, safety and pharmacokinetic study of PF-06647263 in adult patients with advanced solid tumors.
Primary Endpoint	Six (10.00%) patients achieved a confirmed partial response and 22 (36.70%) patients had stable disease. No correlations were observed between tumor responses and EFNA4 expression levels. Study findings showed manageable safety and favorable PK for PF-06647263 administered QW at the RP2D,with preliminary evidence of limited antitumor activity in patients with TNBC and ovarian cancer. Click to Show/Hide
Other Endpoint	The RP2D was determined to be 0.015 mg/kg QW.
Experiment 2 Reporting the Activity Date of This ADC				[2]
*Related Clinical Trial*
NCT Number	NCT02078752	Clinical Status	Phase 1
Clinical Description	A first-in-human phase 1, dose escalation, safety and pharmacokinetic study of PF-06647263 in adult patients with advanced solid tumors.

References

Ref 1	First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors. Int J Cancer. 2019 Oct 1;145(7):1798-1808.
Ref 2	A FIRST-IN-HUMAN PHASE 1, DOSE ESCALATION, SAFETY AND PHARMACOKINETIC STUDY OF PF-06647263 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS